DelveInsight’s “Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Multifocal Leukoencephalopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Progressive Multifocal Leukoencephalopathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Progressive Multifocal Leukoencephalopathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Progressive Multifocal Leukoencephalopathy: An Overview
Progressive Multifocal Leukoencephalopathy (PML) is a neurological disorder characterized by the destruction of cells that produce myelin, an oily substance that helps protect nerve cells in the brain and spinal cord, also known as central nervous system (CNS) white matter. It is caused by a virus called JC virus (JCV)
Progressive Multifocal Leukoencephalopathy symptoms vary from person to person because lesions may occur anywhere in the central nervous system. Most patients present with subacute neurological damage, which may include some degree of mental impairment and a variety of other symptoms such as vision loss, speech disturbances, facial drooping, weakness, problems with coordination, gait, and sensory loss. In addition, approximately one-third of Progressive Multifocal Leukoencephalopathy patients can present with seizures during the course of their disease.
Progressive Multifocal Leukoencephalopathy is characterized by infection of glial cells, namely oligodendrocytes and astrocytes. It is most frequently due to various forms of immunosuppression and can result in significant morbidity and mortality.
The JC virus usually enters the bloodstream during childhood. It can be found via blood tests in healthy children with no Progressive Multifocal Leukoencephalopathy symptoms. Because the virus is also frequently found in the urine of healthy individuals, it is possible that the initial infection may occur through urine-oral contamination. After primary infection, the virus remains inactive in the kidneys and lymphoid organs. The exact mechanisms that lead to JCV activation and the development of Progressive Multifocal Leukoencephalopathy have not been entirely elucidated, but as explained above, most cases occur in the setting of profound cellular immune dysfunction.
There is no specific treatment for JCV. In HIV-positive patients with Progressive Multifocal Leukoencephalopathy, optimization of ART is the best therapeutic option, and in HIV-negative patients, removal or decrease of any potential source of immunosuppression is recommended.
Progressive Multifocal Leukoencephalopathy Market Key Facts
-
A study conducted by Anand et al. (2019), characterized risk factors in patients with confirmed Progressive Multifocal Leukoencephalopathy, HIV infection was the most common risk factor, identified in 49%. Other frequent risk factors included lymphoma, leukemia, or myelodysplasia, identified in 31% of patients; exposure to chemotherapeutic medications 30%; and exposure to monoclonal antibody therapies 19%.
-
As per the National Organization for Rare Disorders (NORD) (2021), Progressive Multifocal Leukoencephalopathy occurs in approximately one in 200,000 people. Each year, it is estimated that 4,000 people develop Progressive Multifocal Leukoencephalopathy in the United States and Europe combined.
-
As per Nakamichi et al. (2023), the incidence rate of Progressive Multifocal Leukoencephalopathy in Japan was 0.029 per 100,000 people, in the study period 2011–2020.
Progressive Multifocal Leukoencephalopathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Progressive Multifocal Leukoencephalopathy pipeline therapies. It also thoroughly assesses the Progressive Multifocal Leukoencephalopathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Progressive Multifocal Leukoencephalopathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Progressive Multifocal Leukoencephalopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Progressive Multifocal Leukoencephalopathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Progressive Multifocal Leukoencephalopathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Progressive Multifocal Leukoencephalopathy Epidemiology, Segmented as –
-
Total Incident Cases of Progressive Multifocal Leukoencephalopathy in the 7MM [2019–2032]
-
Incident Cases of Progressive Multifocal Leukoencephalopathy by Associated Risk Factors in the 7MM [2019–2032]
-
Treatable Cases of Progressive Multifocal Leukoencephalopathy in the 7MM [2019–2032]
Progressive Multifocal Leukoencephalopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Progressive Multifocal Leukoencephalopathy market or expected to be launched during the study period. The analysis covers the Progressive Multifocal Leukoencephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Progressive Multifocal Leukoencephalopathy drugs based on their sale and market share.
The report also covers the Progressive Multifocal Leukoencephalopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Progressive Multifocal Leukoencephalopathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Progressive Multifocal Leukoencephalopathy Market Will Evolve and Grow by 2032 @
Progressive Multifocal Leukoencephalopathy Therapeutics Analysis
There are no FDA-approved medications specifically for Progressive Multifocal Leukoencephalopathy (PML). Effective treatment for the complete cure for Progressive Multifocal Leukoencephalopathy has not been found. Currently, treatment is guided by efforts made to boost the adaptive immune response, and the methods to achieve this goal vary depending on the clinical setting. In HIV patients, prompt initiation of HAART is advised. In transplant patients, the use of multiple immunosuppressive therapies may be limited while weighing the risks of graft rejection. In Progressive Multifocal Leukoencephalopathy induced by natalizumab use, cessation of therapy and resorting to plasma exchange therapy as a means of treatment have been advised.
At present, several agents such as cytosine arabinoside, cidofovir, risperidone, mirtazapine, and mefloquine are being used for the management of Progressive Multifocal Leukoencephalopathy. Further, these agents have been reported to be successful in several cases, but no investigational studies have yet proven their effectiveness.
Several major pharma and biotech companies are developing therapies for Progressive Multifocal Leukoencephalopathy. Currently, NeoImmuneTech is leading the therapeutics market with its Progressive Multifocal Leukoencephalopathy drug candidates in the most advanced stage of clinical development.
CE-VST01-JC, NT-I7, and other emerging therapies are in the early-mid phases of their clinical trials and are awaiting results from their clinical trials. The pipeline contains novel therapies, and launches, which will make the management of the disease possible.
Progressive Multifocal Leukoencephalopathy Companies Actively Working in the Therapeutics Market Include
-
Inhibikase Therapeutics
-
Neurimmune
-
Excision BioTherapeutics
-
I-MAB Biopharma
-
Cellevolve Bio Inc
And Many More
Emerging and Marketed Progressive Multifocal Leukoencephalopathy Therapies Covered in the Report Include:
-
NT-I7: NeoImmuneTech
-
IkT-01427: Inhibikase Therapeutics
-
CE-VST01-JC: Cellevolve Bio Inc
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Progressive Multifocal Leukoencephalopathy Competitive Intelligence Analysis
4. Progressive Multifocal Leukoencephalopathy Market Overview at a Glance
5. Progressive Multifocal Leukoencephalopathy Disease Background and Overview
6. Progressive Multifocal Leukoencephalopathy Patient Journey
7. Progressive Multifocal Leukoencephalopathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Progressive Multifocal Leukoencephalopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Progressive Multifocal Leukoencephalopathy Unmet Needs
10. Key Endpoints of Progressive Multifocal Leukoencephalopathy Treatment
11. Progressive Multifocal Leukoencephalopathy Marketed Therapies
12. Progressive Multifocal Leukoencephalopathy Emerging Drugs and Latest Therapeutic Advances
13. Progressive Multifocal Leukoencephalopathy Seven Major Market Analysis
14. Attribute Analysis
15. Progressive Multifocal Leukoencephalopathy Market Outlook (In US, EU5, and Japan)
16. Progressive Multifocal Leukoencephalopathy Companies Active in the Market
17. Progressive Multifocal Leukoencephalopathy Access and Reimbursement Overview
18. KOL Views on the Progressive Multifocal Leukoencephalopathy Market
19. Progressive Multifocal Leukoencephalopathy Market Drivers
20. Progressive Multifocal Leukoencephalopathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Extracorporeal Circulation System Market
“Extracorporeal Circulation System Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Extracorporeal Circulation System market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. The report provides insight into clinical, commercial & regulatory development in the Extracorporeal Circulation System Market. Furthermore, it also covers emerging products and key companies actively operating in the market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices